CCNL2 and neoplasm: We analyzed by immunohistochemistry (IHC) the expression of ADAT2, CCNL2, DBF4B, and TRIM45 in an exploratory cohort of 45 tumor samples, 26 from patients with no BRCA1 pathogenic variant (WT BRCA1), and 19 from patients with documented BRCA1 pathogenic variant (MT BRCA1) hampering BRCA1 protein production.